ME/CFS statistics in women: prevalence, undiagnosed majority, and funding shortfall

She was 38, a teacher who had not stood through a full class since a viral illness two winters earlier. Clean labs. Normal imaging. A chart full of "fatigue, multifactorial" and one referral note that suggested she was "deconditioned." What she described was not ordinary tiredness. Climbing a flight of stairs left her bedbound the next day. Her heart raced when she stood. She had stopped trusting that any clinician would recognize the pattern.

That pattern has a name: myalgic encephalomyelitis/chronic fatigue syndrome, or ME/CFS. It is a multisystem illness defined by activity-limiting fatigue not relieved by rest, post-exertional malaise, unrefreshing sleep, and either cognitive impairment or orthostatic intolerance lasting more than six months, per the 2015 Institute of Medicine criteria the CDC still uses for diagnosis.

Long COVID coverage keeps pulling ME/CFS numbers into the news for a reason. The two conditions share core features, and a large share of long COVID patients meet ME/CFS criteria. What follows are figures a reporter or clinician can lift with the source named beside them: U.S. prevalence by sex, the post-COVID revision of estimates, the gap between diagnosed and true cases, functional impairment, and research funding relative to burden.

Group	Prevalence
All adults	1.3%
Women	1.7%
Men	0.9%
Ages 18-39	0.7%
Ages 50-59	2.0%
Ages 60-69	2.1%
Age 70 and older	1.4%

Source: Vahratian A, et al. NCHS Data Brief No. 488, December 2023. Self-reported doctor diagnosis of ME/CFS still present at interview; 2021-2022 National Health Interview Survey.

Fiscal year	Funding ($ millions)
2016	8
2017	15
2018	14
2019	15
2020	15
2021	17
2022	13
2023	13
2024	13
2025	12

Source: NIH Research, Condition, and Disease Categorization (RCDC) categorical spending estimates for Chronic Fatigue Syndrome (ME/CFS). Dollars in millions; amounts are NIH category estimates and can include projects with partial ME/CFS relevance.

How common ME/CFS is, and the female majority

Start with the cleanest national number we have. During 2021-2022, 1.3% of U.S. adults had myalgic encephalomyelitis/chronic fatigue syndrome, according to the National Center for Health Statistics analysis of the National Health Interview Survey. That estimate rests on two survey questions: whether a doctor or other health professional ever said the person had CFS or ME, and whether they still had it.

Women carried nearly twice the burden. The same NCHS brief put prevalence at 1.7% among women and 0.9% among men. That is not a clinic-cohort artifact. It is a nationally representative household survey of more than 57,000 adults. A 2020 systematic review and meta-analysis by Lim and colleagues in the Journal of Translational Medicine found the same direction of effect across case definitions: women about 1.5 to 2 times more likely to meet criteria than men, with a meta-analytic female prevalence of 1.36% versus 0.86% in men under pooled models.

Age follows a recognizable curve. Prevalence rose from 0.7% at ages 18-39 to 2.0% at ages 50-59 and 2.1% at ages 60-69, then fell to 1.4% at age 70 and older, per NCHS. CDC Fast Facts still notes that ME/CFS is most common between ages 40 and 60, which matches where the survey peaks.

The income and rurality patterns cut against older stereotypes. Adults with family income below 100% of the federal poverty level had ME/CFS at 2.0%, compared with 1.1% among those at or above 200% of poverty. Prevalence also rose with rurality: 1.0% in large central metro counties, 1.1% in large fringe metro areas, 1.5% in medium and small metros, and 1.9% in nonmetropolitan areas. The "yuppie flu" framing never matched the data; the 2021-2022 survey makes that explicit.

By race and Hispanic origin, non-Hispanic White adults (1.5%) were more likely to report diagnosed ME/CFS than Hispanic (0.8%) or non-Hispanic Asian adults (0.7%). Non-Hispanic Black adults sat at 1.2%. Those figures measure who carries a diagnosis, not who has the biology. CDC Fast Facts notes that people who are Black and Latino may be more affected in community-based studies. Diagnostic access and survey self-report can pull in opposite directions.

CDC currently cites a U.S. range of 836,000 to 3.3 million people with ME/CFS. The lower bound reflects pre-pandemic community studies cited by the Institute of Medicine in 2015; the upper bound aligns with the NHIS diagnosis-based estimate of about 3.3 million adults (1.3% of adults). NCHS notes that because its 1.3% figure requires a doctor's diagnosis, true prevalence is higher than the survey captures.

How COVID revised the prevalence picture

Before the pandemic, the working U.S. estimate that many researchers used sat near 1 to 2.5 million people. The 2015 Institute of Medicine report summarized community studies placing the range at 836,000 to 2.5 million. Mirin and colleagues, updating their burden analysis in 2022 in Fatigue: Biomedicine, Health & Behavior, put pre-COVID prevalence at about 1.5 million and annual economic impact at $36 to $51 billion.

Then SARS-CoV-2 arrived, and the infection-triggered pathway that clinicians had long described in ME/CFS became impossible to ignore. In their 2022 update, Mirin and colleagues estimated that total U.S. ME/CFS prevalence could rise to between 5 and 9 million people because of post-acute sequelae of COVID-19, with annual medical expenses and lost income of $149 to $362 billion (exclusive of disability benefits, social services, and caregiver wages).

That projection is a model, not a new NHIS measurement. Treat it as an upper-bound scenario grounded in infection volume and post-viral conversion rates. What the clinical literature has measured more tightly is the overlap itself. A 2024 systematic review and meta-analysis by Dehlia and Guthridge in the Journal of Infection pooled 13 studies totaling 1,973 long COVID patients and found that 51% (95% CI 42-60%) satisfied ME/CFS diagnostic criteria. Fatigue, sleep disruption, and muscle or joint pain were the most common shared symptoms; post-exertional malaise was present as well.

That half-overlap is why long COVID coverage keeps citing ME/CFS numbers, and why the two conditions should not be treated as unrelated public-health problems. Our review of long COVID statistics in women covers the sex disparity on the post-COVID side; the short version is that women also carry a larger share of long COVID, which multiplies the female burden when the two illnesses intersect.

The NCHS 2021-2022 survey sits awkwardly between eras. It is the best national diagnosis-based snapshot we have, and it already includes early pandemic years, but it cannot fully capture later waves or people who still lack a clinician willing to name the condition. True prevalence after repeated national infection waves is almost certainly higher than 1.3% of adults. How much higher is the open question the field is still measuring.

Diagnosed rate versus estimated true prevalence

If you remember one diagnostic statistic, make it this one: about 9 in 10 people with ME/CFS have not been diagnosed, according to CDC Fast Facts updated in May 2024. The Institute of Medicine's 2015 consensus report put the undiagnosed share at 84% to 91%, citing earlier community studies by Jason and by Solomon and Reeves. CDC's current language is a rounder restatement of that same gap.

The NCHS survey is explicit about what it misses. Its 1.3% figure counts adults who were told they had ME/CFS by a clinician and still had it. People who meet research criteria but never received the label are outside the frame. That is why CDC can simultaneously report a 1.3% diagnosis rate and a population range running into the millions, and why both can be true.

Diagnostic delay is part of the same story. The IOM report found that 67% to 77% of patients said it took more than a year to receive a diagnosis, and about 29% of those patients said it took more than five years. Less than one-third of medical schools included ME/CFS-specific information in the curriculum at the time of that review. Those are older figures; awareness has improved since long COVID forced post-viral illness into primary care. But the structural problem has not disappeared: no biomarker, contested legitimacy, and a long history of psychologizing women's symptoms.

Insurance-claims work lands in a similar band once you accept that diagnosis is incomplete. Valdez and colleagues, writing in Frontiers in Pediatrics in 2019, estimated that 1.7 million to 3.38 million people in the United States may carry a diagnosis of ME or CFS based on large claims data, with a machine-learning model predicting about 2.8 million (857 per 100,000). They also noted that 35% to 40% of diagnosed patients were men. ME/CFS is female-predominant, not female-exclusive.

Case definition changes the count. Lim's 2020 meta-analysis put prevalence at 0.89% under the widely used CDC-1994 (Fukuda) definition, with far lower rates under the older Holmes criteria and higher rates under broader interview-based methods. The IOM/SEID clinical criteria the CDC now recommends for diagnosis require the three core symptoms plus either cognitive impairment or orthostatic intolerance. Different nets catch different fish. When reporters compare a 1990s community study with a 2022 diagnosis survey, they are often comparing different fish entirely.

The practical implication for clinicians is blunt. A normal CBC and thyroid panel do not rule out ME/CFS. Diagnosis is clinical, based on history and the exclusion of alternative explanations. Waiting for a perfect test is how patients spend years in limbo.

Functional impairment and quality of life

ME/CFS is not "being tired." The defining feature is post-exertional malaise: a delayed worsening of symptoms after physical, cognitive, or emotional exertion that would not have caused problems before illness. CDC describes recovery from a PEM crash as taking days, weeks, or longer. People with the illness are often unable to do previous activities; some are homebound or bedbound.

How often is that severe end of the spectrum? Conroy and colleagues examined an international aggregated sample of 2,138 people with ME/CFS and classified 25.7% (549 people) as homebound: unable to work or leave the home for light housework. Within the homebound group, 16.2% (89 of 549) were bedridden. Using a U.S. prevalence of about 1.5 million, the authors estimated roughly 385,000 homebound Americans with ME/CFS and about 62,000 bedridden. Advocacy groups had long used a "25% severe" rule of thumb; this study put an empirical number under it, with the caveat that convenience and clinic samples can over-represent severe disease relative to community surveys.

Quality-of-life comparisons are stark. Falk Hvidberg and colleagues, writing in PLoS ONE in 2015, measured EQ-5D-3L health-related quality of life in a Danish ME/CFS patient association sample. The unadjusted mean score was 0.47, against a population mean of 0.85. That was the lowest mean among 20 compared conditions in their analysis, worse than stroke and multiple sclerosis on the same instrument. Only 7.6% of the ME/CFS sample was employed, versus 52.2% in the reference population; 52.2% were on disability pension versus 5.2% in the population sample. The cohort was 87.2% women, which tracks the female majority and the membership of a patient association.

NCHS places the economic cost of ME/CFS to the U.S. economy at about $18 to $51 billion annually, drawing on earlier community and utilization studies. The 2015 IOM report cited $17 to $24 billion in direct and indirect costs, including $9.1 billion in lost household and job productivity. Mirin's 2022 post-COVID revision scales those figures into the low hundreds of billions if prevalence climbs into the multi-million range. Exact dollars move with prevalence assumptions; the direction does not.

The functional picture overlaps with other poorly understood, female-predominant conditions. Many patients also meet criteria for fibromyalgia, migraine, or orthostatic intolerance, and the diagnostic odyssey often runs through the same specialties. Our coverage of fibromyalgia statistics and sleep disorders in women describes adjacent pieces of that map. When illness disrupts cycles and fertility planning, as chronic systemic disease often does, tools such as our period calculator and cycle length calculator can help patients track what is changing, even when the primary problem is not gynecologic.

Research funding relative to disease burden

Here is the funding gap in plain language. The NIH's categorical spending table has long placed ME/CFS near the bottom of disease categories. In fiscal years 2022 through 2024, NIH RCDC estimates for Chronic Fatigue Syndrome (ME/CFS) held at about $13 million per year. Funding peaked near $17 million in 2021 and has since drifted down toward $12 million in the 2025 estimate. For a condition affecting millions of people, those are small numbers.

How small relative to burden? Mirin and colleagues, updating their analysis in Work in 2020, found ME/CFS more underfunded with respect to disease burden than any disease in NIH's own funding-versus-burden framework, receiving roughly 7% of the funding that would be commensurate with burden. They estimated a roughly 14-fold increase would be needed to reach parity. Their 2022 post-COVID update raised the bar further: if prevalence climbed to 5-9 million, burden-commensurate NIH funding would need to reach approximately $472 to $600 million annually, up to a 40-fold increase from the then-current $15 million.

A 2026 analysis by Bonuck and colleagues in Communications Medicine sharpened the same conclusion with newer disability metrics. Using years lived with disability (YLDs) and average NIH funding for fiscal years 2022-2024, they found ME/CFS was the most underfunded condition among those analyzed, receiving less than 1% of its YLD-proportionate funding. Long COVID itself received only 14% of disability-commensurate funding ($106 million versus $739.8 million). Across conditions, median funding per YLD was 5.2 times higher for male-predominant than female-predominant diseases ($7.03 versus $1.29 million per YLD). That sex pattern is not unique to ME/CFS, but ME/CFS sits at the extreme end of it.

The funding shortfall is not abstract. There is still no FDA-approved treatment for ME/CFS, no validated biomarker in routine care, and limited clinical-trial infrastructure. Underfunding compounds the diagnostic gap: few specialists, thin medical-school curricula, and primary care taught to treat unexplained fatigue as a psychiatric residual rather than a post-infectious disease state.

This is the same architecture we describe in our analysis of the research funding gap in women's health and in data on disability and women's healthcare access. Female-predominant, poorly biomarker-defined conditions lose twice: once in the clinic, where symptoms are minimized, and again in the budget, where disability burden fails to convert into research dollars.

None of this means ME/CFS is hopeless. Pacing to avoid PEM, treating orthostatic intolerance, and addressing sleep and pain help some patients function better. Management is not a cure, and management research itself needs funding. Until NIH spending moves closer to burden, the trial pipeline will stay thin relative to the number of people sitting in exam rooms with normal labs and a life they can no longer live.

Frequently asked questions about ME/CFS in women

How common is ME/CFS in women in the United States?

In 2021-2022, 1.7% of U.S. adult women had ME/CFS compared with 0.9% of men, according to the CDC National Center for Health Statistics analysis of the National Health Interview Survey. Overall adult prevalence was 1.3%. Because the survey counts only people with a clinician diagnosis, true rates are higher than those figures.

Why is ME/CFS more common in women?

Population surveys and meta-analyses consistently show women about 1.5 to 2 times more likely to have ME/CFS than men. Proposed mechanisms include immune and hormonal differences after infection, but the cause of ME/CFS is still unknown. Diagnostic bias may also affect who receives a label; community studies have sometimes found higher rates in underdiagnosed groups than clinic records alone suggest.

How many people with ME/CFS are undiagnosed?

CDC states that about 9 in 10 people with ME/CFS have not been diagnosed. The 2015 Institute of Medicine report estimated that 84% to 91% of people with the illness were undiagnosed. There is no specific diagnostic test; clinicians use the 2015 IOM case definition after history and exam, with an appropriate work-up.

Did COVID-19 increase ME/CFS prevalence?

Yes, that is the expected direction. A 2024 meta-analysis found 51% of long COVID patients met ME/CFS diagnostic criteria. Mirin and colleagues estimated in 2022 that U.S. ME/CFS prevalence could rise from about 1.5 million pre-pandemic to between 5 and 9 million after accounting for post-COVID cases. National diagnosis surveys have not yet fully measured that shift.

How disabling is ME/CFS?

In a 2,138-person international sample, 25.7% of people with ME/CFS were homebound (Conroy, Jason et al., 2021). A Danish EQ-5D study found mean health-related quality of life of 0.47 versus 0.85 in the general population, the lowest among 20 conditions compared. NCHS cites U.S. economic costs of about $18 to $51 billion annually.

How does NIH research funding for ME/CFS compare with disease burden?

NIH categorical funding for ME/CFS has recently been about $12 to $13 million per year. A 2026 analysis in Communications Medicine found ME/CFS received less than 1% of the funding that would be proportional to its years lived with disability, the most severe underfunding among conditions studied. Earlier work by Mirin and colleagues estimated funding at roughly 7% of burden-commensurate levels and called for large increases.